Kanamycin sulfate(CAS: 70560-51-9)

Kanamycin sulfate (CAS: 70560-51-9) is regulated under various guidelines including the Globally Harmonized System of Classification and Labelling of Chemicals (GHS), REACH regulations in the European Union, and requirements from the U.S. Food and Drug Administration (FDA) and Environmental Protection Agency (EPA). Manufacturers must comply with these regulations for labeling, transportation, and environmental protection.

There are several alternatives to Kanamycin sulfate (CAS: 70560-51-9) in synthesis, such as gentamicin sulfate and amikacin sulfate, which are also aminoglycoside antibiotics. Other substitutes include synthetic analogs and isomers like tobramycin. These alternatives offer similar antibacterial properties but may have different pharmacokinetic profiles and potential side effects.

Kanamycin sulfate (CAS: 70560-51-9) is experiencing a stable demand in the pharmaceutical industry, particularly in treating infections caused by gram-negative bacteria. Research trends focus on understanding its mechanism of action, developing resistance management strategies, and exploring its use in combination therapies. Additionally, there is interest in developing more potent analogs and reducing side effects.

Waste containing Kanamycin sulfate (CAS: 70560-51-9) should be managed according to local regulations. It is recommended to collect waste in appropriate containers, ensure proper labeling, and dispose of it through a licensed hazardous waste disposal service. Incineration or professional waste disposal methods are common, and environmental protection measures should be taken to prevent contamination and ensure worker safety.